CNBC's Jim Cramer on Wednesday gave his take on Hims & Hers Health , a digital platform that offers telehealth services, particularly for sexual health, mental health, weight loss and skin care.
Cramer suggested it might be worth starting a position in the stock now that it's pulled back some from recent highs.
"While it makes sense that the stock roared on this compounded GLP-1 news, I don't love that it's now trading on what's essentially a temporary business," he said.
Those great first quarter numbers didn't have any benefit from knock-off GLP-1s, and I bet the business stays strong."
Hims & Hers Health did not respond immediately to request for comment.
Persons:
CNBC's Jim Cramer, Cramer, it's, I'd, —, Eli Lilly, dalliance
Organizations:
Wednesday, HIMS, Novo Nordisk